Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease
- 18 March 1997
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 7 (6) , 699-704
- https://doi.org/10.1016/s0960-894x(97)00080-2
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Potent Human Immunodeficiency Virus Type 1 Protease Inhibitors That Utilize Noncoded d-Amino Acids as P2/P3 LigandsJournal of Medicinal Chemistry, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Structure-Based Design of Novel HIV Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic InhibitorsJournal of Medicinal Chemistry, 1995
- Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 proteaseJournal of the American Chemical Society, 1994
- Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modesJournal of Medicinal Chemistry, 1991
- Structure-based, C2 symmetric inhibitors of HIV proteaseJournal of Medicinal Chemistry, 1990
- Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy TransferScience, 1990
- Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450Xenobiotica, 1987